NETRF is excited to announce that applications are now open for the Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs), developed in partnership with
By Anna Greene, PhD, NETRF Director of Research What if small intestine neuroendocrine tumors (SI-NETs), often diagnosed in people over age 60, actually begin decades
By Anna Greene, PhD, NETRF Director of Research An important advancement in neuroendocrine neoplasm (NEN) patient care has been released: the Position Statement on Nutritional
The world’s first clinical trial for CAR T-cell therapy in neuroendocrine tumors has advanced to a higher dose level, an indication of progress. Advancing to
By Anna Greene, PhD, NETRF Director of Research For many patients newly diagnosed with small, nonfunctioning pancreatic neuroendocrine tumors (PanNETs), active surveillance (AS) with regular
By Anna Greene, PhD, NETRF Director of Research A recent study by Suriya Baskar, MD, and Udhayvir Singh Grewal, MD, published in the Journal of
Perspective Therapeutics has begun enrolling participants into the next phase of its clinical trial of a new targeted alpha radiation therapy for neuroendocrine tumors (NETs).
“Where do you see yourself in five years?” I’ve stopped answering that question. Five years ago I was 31. Five years ago I was planning my wedding. Five
At the Neuroendocrine Tumor Research Foundation (NETRF), we believe that the path to better treatments and cures, starts with research. However, ensuring that we fund
By Anna Greene, PhD, NETRF Director of Research The landscape of biomedical research is undergoing a seismic shift. This year alone, the NIH has awarded